FORM 4

obligations may continue. See

Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

## OMB APPROVAL OMB Number: 3235-0287 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Estimated average burden

hours per response:

E. Dolotionship of Deporting Person(e) to Issuer

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2 Jacuar Nama and Tieker or Trading Cumbel

Name and Address of Reporting Person     Alland Leila					PMV Pharmaceuticals, Inc. [ PMVP ]								all appli Directo	cable) or	10% (		)wner
(Last) (First) (Middle) C/O PMV PHARMACEUTICALS, INC. 8 CLARKE DRIVE, SUITE 3					3. Date of Earliest Transaction (Month/Day/Year) 05/07/2021							Х	below) below)  Chief Medical Officer			poony	
(Street) CRANBURY NJ 08512  (City) (State) (Zip)				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
	Tab	le I - I	Non-Deri	vativ	e Sec	urities A	cquire	ed, C	Disposed o	of, or E	Benefic	ially	Owned	i			
			Date		Execu if any	tion Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			5)	Securiti Benefic Owned	5. Amount of Securities Beneficially Owned Following		Direct Indirect Istr. 4)	7. Nature of Indirect Beneficial Ownership
							Code	v	Amount	(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)				Instr. 4)
Common Stock			05/07/2021				М		4,000	A	\$3.	.9	4	4,000		D	
Common Stock			05/07/2021				S <sup>(1)</sup>		3,842	D	\$34.	8(2)	1	158		D	
Common Stock				05/07/2021			S <sup>(1)</sup> 158 D \$35		\$35.48	391 <sup>(3)</sup>		0		D			
	7	<b>Table</b>					•	,	•	,		•	wned				
or Exercis Price of	ercise (Month/Day/Year) if any of (Month/Day/Year) ative					6. Date Exercisable and Expiration Date (Month/Day/Year)			(Instr. 3 and 4)		ity De Se	Derivative Security (Instr. 5) derivative Securitie Beneficia Owned Following Reported		ly G	Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
	Leila  V PHARI KE DRIV  URY  Security (In  Stock Stock Stock Stock Conversio or Exercis Price of Derivative	Leila  (First) V PHARMACEUTICALS, KE DRIVE, SUITE 3  URY NJ  (State)  Tab  Security (Instr. 3)  Stock Stock Stock Stock Stock Stock Stock Stock Month/Day/Year)	Leila  (First) (Middle V PHARMACEUTICALS, INC. KE DRIVE, SUITE 3  URY NJ 08512  (State) (Zip)  Table I - I  Security (Instr. 3)  Stock  Stock  Stock  2.  Conversion or Exercise Price of Derivative Price of Derivative  Stock  1. Stock  2. Stock  Conversion of Exercise (Month/Day/Year)  Conversion of Exercise (Month/Day/Year)  Conversion of Exercise (Month/Day/Year)  Conversion of Exercise (Month/Day/Year)	Leila  (First) (Middle)  V PHARMACEUTICALS, INC.  KE DRIVE, SUITE 3  URY NJ 08512  (State) (Zip)  Table I - Non-Deriv  Security (Instr. 3) 2. Transact Date (Month/Day)  I Stock 05/07/2  I Stock 05/07/2  Table II - Deriva (e.g., p. 1)  Conversion or Exercise Price of Derivative (Month/Day/Year)  2. (Stock 05/07/2)  Table III - Deriva (e.g., p. 1)	Conversion or Exercise Price of Derivative (e.g., puts, Pare of Derivative (Month/Day/Year)   Code of Deri	Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price of Derivative Security (Instr. 3)   Conversion or Exercise Price	Conversion or Exercise Price of Derivative Security   Security	Code   Conversion or Exercise Price of Derivative Security   Sec	Code   Interest   Conversion or Exercise Price of Derivative Security	Conversion or Exercise Price of Detervative Security   Security	Code   V   Amount   Code   Conversion   Os/07/2021   Stock   Os/07/2021   Os/07/202	Concession of Exercise of Derivative Securities Acquired, Disposed of, or Beneficial (P.G. Internation Date (P.G	Check   PMVP   Pharmaceuticals, Inc.   PMVP     Check   X	PMV Pharmaceuticals, Inc. [PMVP]   Check all application Date (First) (Middle)   Check all application Date (First) (Month/Day/Year) (State) (State) (Zip)   A. If Amendment, Date of Original Filed (Month/Day/Year)   Continue	PMV Pharmaceuticals, Inc. [PMV]   Check all applicable)   Director   Director   Officer (give title below)   O5/07/2021   Scurities Acquired (A) or Person   Officer (give title below)   Chief Med   Chief Med	Check all applicables   Director   Director   Check all applicables   Director   Competition   Competition   Competition   Check all applicables   Director   Competition   Competitio	PMV Pharmaceuticals, Inc.   PMVP     Check all applicable)   Director   10% Ownership   Conversion   Oxfor/2021   Stock   Oxfor/2021   Ox

## **Explanation of Responses:**

\$3.9

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

Code

M

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.30 to \$35.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Date Exercisable

(4)

(D)

4,000

(A)

Expiration Date

02/04/2030

Title

Stock

- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.47 to \$35.50, inclusive.
- 4. One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter.

## Remarks:

Employee Stock Option

(right to buy)

> /s/ Winston Kung, by power of 05/10/2021 attorney

or Number

4,000

\$0.00

369,850

D

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

05/07/2021

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.